Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
26 June 2020Website:
http://fusionpharma.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 04 Jun 2024 20:00:00 GMTDividend
Analysts recommendations
Institutional Ownership
FUSN Latest News
HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. The Arrangement marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
Fusion (FUSN) is anticipated to share updates on the progress of its main candidate, FPI-2265, for prostate cancer during the first-quarter earnings report.
Fusion Pharmaceuticals Inc. (FUSN) ended the latest trading session at $21.36, showing no change from the day before.
AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.
HAMILTON, ON and BOSTON , March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. Presentation at AACR Annual Meeting 2024: Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) Session: Phase II Clinical Trials 1 Session Date and Time: Tuesday April 9, 2024, 9:00 a.m – 12:30 p.m.
Fusion Pharmaceuticals is an oncology company focused on precision medicine and radiopharmaceuticals. The company's clinical candidates show promise in targeting and treating cancers with unmet needs. Fusion has a strong financial position, with enough cash to fund operations until Q2 2025, and strategic partnerships to support its clinical pipeline.
Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.
HAMILTON, ON and BOSTON , Feb. 26, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming investor conferences. TD Cowen 44th Annual Health Care Conference - The Company will participate in the "Prostate Cancer Corporate Panel Discussion" taking place on March 4, 2024, at 10:30 a.m.
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Fusion Pharmaceuticals Inc. (FUSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Fusion Pharmaceuticals Inc. (FUSN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 1(current)
What type of business is Fusion Pharmaceuticals?
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
What sector is Fusion Pharmaceuticals in?
Fusion Pharmaceuticals is in the Healthcare sector
What industry is Fusion Pharmaceuticals in?
Fusion Pharmaceuticals is in the Biotechnology industry
What country is Fusion Pharmaceuticals from?
Fusion Pharmaceuticals is headquartered in Canada
When did Fusion Pharmaceuticals go public?
Fusion Pharmaceuticals initial public offering (IPO) was on 26 June 2020
What is Fusion Pharmaceuticals website?
https://fusionpharma.com
Is Fusion Pharmaceuticals in the S&P 500?
No, Fusion Pharmaceuticals is not included in the S&P 500 index
Is Fusion Pharmaceuticals in the NASDAQ 100?
No, Fusion Pharmaceuticals is not included in the NASDAQ 100 index
Is Fusion Pharmaceuticals in the Dow Jones?
No, Fusion Pharmaceuticals is not included in the Dow Jones index
When does Fusion Pharmaceuticals report earnings?
The next expected earnings date for Fusion Pharmaceuticals is 08 August 2024